SLC5A2 and metabolic dysfunction-associated steatohepatitis: To our knowledge, this is the first study investigating the effects of the new, long-acting GLP-1 agonist dulaglutide and the SGLT-2 inhibitor empagliflozin alone and in combination in a dietary mice model for non-alcoholic steatohepatitis.